Fibrocell Science — Investor Presentation (May 2016)
24 slides from Fibrocell Science's investor presentation, May 18, 2016
Slide 1: Corporate Presentation May 18, 2016
Corporate Presentation May 18, 2016
Slide 2: Forward-Looking Statements
This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among ot
Slide 3: Company Highlights
Company Highlights • Cell and gene therapy company developing a pipeline of autologous biologics for localized treatment of diseases affecting the skin, connective tissue and joints Pipeline based on proprietary fibroblast platform • Phase II azficel-T program for Vocal Cord Scarring resulting in C
Slide 4: Autologous Fibroblasts as a Platform for Therapy
Autologous Fibroblasts as a Platform for Therapy • Fibroblasts repair tissue infrastructure by producing extracellular matrix proteins including collagen and growth factors •Most common cell in skin and connective tissue •Key advantages of our autologous fibroblast platform for creating cell and gen
Slide 5: Two Product Engines – Multiple Therapeutics in Development
Two Product Engines – Multiple Therapeutics in Development 5 Personalized Biologics Approach
Slide 6: Manufacturing Expertise
• Leveraging existing azficel-T BLA and cell manufacturing process for all pipeline candidates (Genetically-Modified & non-GM) • Experts in cGMP manufacturing of autologous fibroblasts •Operator of cGMP cell therapy manufacturing facility routinely inspected by FDA for production of azficel-T •Proce
Slide 7: Development Pipeline
Development Pipeline 7 Personalized Biologics Indication Research Pre-Clinical Development Phase I Phase II Phase III azficel-T* Vocal Cord Scarring Resulting in Chronic or Severe Dysphonia FCX-007√ Orphan Product Candidate Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013√ Orphan Product Ca
Slide 8: Vocal Cord Scarring Resulting in Chronic or Severe Dysphonia
Vocal Cord Scarring Resulting in Chronic or Severe Dysphonia 8 Disease Current Treatments Epidemiology Damage to the fibroblast layer causes scarring and edema, which limits air flow and results in severe and significant limitations in voice quality, often loss of voice Current treatments only addre
Slide 9: Clinical Data Support Our Approach in Vocal Cord Scarring
Clinical Data Support Our Approach in Vocal Cord Scarring Positive Phase I clinical trial results published in peer-reviewed journal2 • Injection of azficel-T into scarred vocal cord was well-tolerated in trial (n=5) All patients completed the trial No serious adverse events reported •Positive tre
Slide 10: Vocal Cord Scarring—Phase II Trial
Vocal Cord Scarring—Phase II Trial 10 •Double-blind, randomized, placebo-controlled (21 subjects) One dose per vocal cord per month x 3 treatments Last subject visit completed for primary endpoint analysis April 2016 • Primary endpoint: Four-month efficacy on three different scales Voice Handicap
Slide 11: Recessive Dystrophic Epidermolysis Bullosa
Recessive Dystrophic Epidermolysis Bullosa 11 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate • Current treatments only a
Slide 12: FCX-007 Providing Hope for RDEB Patients
FCX-007 Providing Hope for RDEB Patients 12 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1
Slide 13: Detection of COL7 Expression by Immunofluorescence
13 Detection of COL7 Expression by Immunofluorescence • In vitro COL7 expression noted from FCX-007 replicates (red) • FCX-007 expresses higher levels of COL7 than normal human dermal fibroblasts (NHDF) as depicted by a brighter signal • No expression in RDEB-positive cells NHDF RDEB+ FCX-007 Replic
Slide 14: COL7 Expression Confirmation
COL7 Expression Confirmation 14 Culture supernatant evaluated for in vitro COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruckner-Tuder
Slide 15: COL7 Persistence
The persistence of COL7 expressed by FCX-007 will be evaluated in clinical trials. We believe persistence will be long-lasting due to: • Autologous cells having less rejection risk • Direct administration of FCX-007 to the upper dermis ensures COL7 is expressed in the vicinity of the basement membra
Slide 16: FCX-007 Phase I/II Clinical Trial Design
FCX-007 Phase I/II Clinical Trial Design 16 Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Statement of Purpose The purpose of this study is threefold: 1) To evaluate the safety of FCX-007 2) To eva
Slide 17: Linear Scleroderma
Linear Scleroderma 17 Disease Epidemiology • Excess production of collagen I and III characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions ap
Slide 18: FCX-013 Development Progressing
FCX-013 Development Progressing 18 •Product profile Autologous fibroblasts genetically modified using lentivirus and encoded for a protein responsible for breaking down excess collagen I and III Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) •Proof-of-concept animal study data achi
Slide 19: FCX-013 Proof-of-Concept Study
FCX-013 Proof-of-Concept Study 19 • Study Design Bleomycin treated SCID mouse model N=30 mice over test and control groups Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result Bleomycin treatment resulted in skin
Slide 20: RheoSwitch Control
• FCX-013 employs Intrexon’s RheoSwitch Therapeutic System® (RTS®) The RTS® biologic switch is activated by an orally- administered activator ligand (AL) that provides the ability to control level and timing of protein expression in those diseases where such control is ideal • Enhances the safety
Slide 21: New Gene Therapy Collaboration with Intrexon
New Gene Therapy Collaboration with Intrexon 21 •Goal is to deliver a protein therapy locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy • Collaboration combines Fibrocell’s autologous fibroblast technology with Intrexon’s cel
Slide 22: Expected Milestones & Corporate Information
Expected Milestones & Corporate Information 22 •Cash = $13.1 million at 31 Mar 2016 (unaudited) •43.9 million common shares of FCSC outstanding at 31 Mar 2016 5.3 million warrants; 4.0 million options Expected Milestones Timing FCX-007 Phase I/II Trial Initiation June 2016 azficel-T Phase II Data
Slide 23: Company Highlights
Company Highlights • Cell and gene therapy company developing a pipeline of autologous biologics for localized treatment of diseases affecting the skin, connective tissue and joints Pipeline based on proprietary fibroblast platform • Phase II azficel-T program for Vocal Cord Scarring resulting in C
Slide 24: References
References 1Data on file. Fibrocell Science, Inc. 2Chhetri D, et al. Injection of cultured autologous fibroblasts for human vocal fold scars. The Laryngoscope. 2011;121(4):785-792. 3The Dystrophic Epidermolysis Research Association of America (DebRA). DEB brochure, page 6: http://www.debra.org/pdfs/